How to Check Symbiotec Pharmalab IPO Allotment Status

Symbiotec Pharmalab Ltd. is a research-driven pharmaceutical and biotechnology company with capabilities across three platforms: organic chemistry, biotechnology and complex injectables. The company develops and manufactures active pharmaceutical ingredients (APIs), biotechnology products and complex injectable formulations, serving customers across more than 40 countries.

About the Symbiotec Pharmalab Ltd. IPO

Symbiotec Pharmalab IPO was a ₹1,757 crore book-built mainboard issue comprising a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore by existing shareholders. The IPO opened for subscription on August 24, 2026 and closed on August 27, 2026. 

The basis of allotment was finalised on August 28, 2026. Refunds to unsuccessful applicants and credit of shares to successful bidders are scheduled for August 31, 2026. The shares are tentatively scheduled to list on BSE and NSE on September 1, 2026. 

The IPO was priced at ₹988 per share, with a lot size of 15 shares. JM Financial Ltd. acted as the book-running lead manager, while MUFG Intime India Pvt. Ltd. was appointed as the registrar to the issue. 

Registrar: MUFG Intime India Pvt. Ltd.

 NSE: NSE IPO Allotment Status Page 

 BSE: BSE IPO Allotment Status Page 

Symbiotec Pharmalab Ltd. IPO Subscription Status

Symbiotec Pharmalab IPO witnessed strong investor demand and was subscribed 75.08 times overall at the close of bidding on August 27, 2026. Demand was led by institutional investors, with QIB participation surging sharply on the final day.

The QIB category witnessed a sharp surge in bids on the final day and closed at 181.20 times subscription, indicating significant institutional interest in the issue.  

The NII category was subscribed 77.56 times, reflecting strong demand from high-net-worth investors. 

Retail investors subscribed their reserved portion 13.69 times, while the employee category received bids equivalent to 16.32 times its allocated shares. 

Overall subscription rose from 0.85 times on Day 1 to 75.08 times on the final day, driven primarily by institutional participation during the closing hours of the issue.

Symbiotec Pharmalab Ltd. IPO Share Price and Investment Details

Symbiotec Pharmalab IPO was priced at ₹988 per share. With a lot size of 15 shares, the minimum investment required by a retail investor worked out to ₹14,820. 

The IPO comprised approximately 1.78 crore equity shares aggregating to ₹1,757 crore. Of the total issue size, the fresh issue component amounted to ₹150 crore, while the offer for sale accounted for ₹1,607 crore. 

Based on the final subscription figures, QIBs led demand at 181.20 times, followed by NIIs at 77.56 times, employees at 16.32 times and retail investors at 13.69 times. Overall subscription stood at 75.08 times. 

Given the substantial oversubscription across categories, allotment remained highly competitive. The basis of allotment was finalised on August 28, ahead of the proposed September 1, 2026 listing.

Utilisation of IPO Proceeds

Symbiotec Pharmalab proposes to utilise the proceeds from the fresh issue primarily towards strengthening its balance sheet through debt reduction. The company intends to deploy approximately ₹112.5 crore towards the prepayment and/or repayment, in full or in part, of certain outstanding borrowings. 

By reducing debt, the company expects to lower its finance costs and improve financial flexibility, which may support future business growth and expansion initiatives. 

The remaining proceeds from the fresh issue are proposed to be utilised for general corporate purposes and other business requirements. 

Since ₹1,607 crore of the ₹1,757 crore IPO comprises an offer for sale, Symbiotec Pharmalab will not receive the proceeds attributable to shares sold by existing shareholders. Those proceeds will be received directly by the selling shareholders. 

The utilisation mix indicates that the fresh issue capital is primarily focused on debt reduction and strengthening the company's financial position.

Since the IPO also includes an Offer for Sale (OFS) of ₹184 crore, Skyways Air Services will not receive the proceeds attributable to shares sold by the existing shareholders. Those proceeds will go directly to the selling shareholders. 

This utilisation mix indicates that the fresh capital is largely aimed at improving the balance sheet through debt reduction while simultaneously supporting future growth through enhanced working capital availability.